ARS Pharmaceuticals Advances Clinical Program for Intranasal Epinephrine Spray

SAN DIEGO–(BUSINESS WIRE)–ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions potentially leading to anaphylaxis, has raised $20 million in Series C financing led by Deerfield Management. The Company will use the funds to advance the clinical development of its novel intranasal epinephrine spray, ARS-1, which could provide an easy-to-use, convenient and more reliable treatment f